MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/140/0.1/17.01.25 | Real-time Bid/Ask 13:22:05 2024-07-01 EDT | ||
| 1.74 EUR / 1.75 EUR | +6.40% |
|
| Current month | +43.86% | ||
| 1 month | +41.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 1.59 | -3.05% |
| 24-06-28 | 1.64 | -1.80% |
| 24-06-27 | 1.67 | 0.00% |
| 24-06-26 | 1.67 | -8.74% |
| 24-06-25 | 1.83 | +19.61% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 08:50 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME1GBQ |
| ISIN | DE000ME1GBQ8 |
| Date issued | 2023-10-03 |
| Strike | 140 $ |
| Maturity | 2025-01-17 (200 Days) |
| Parity | 10 : 1 |
| Emission price | 0.28 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.83 € |
|---|---|
| Lowest since issue | 0.219 € |
| Spread | 0.01 € |
| Spread % | 0.57% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Warrants
- Warrant
